benfotiamine / Generic mfg. - LARVOL DELTA

Thiamine as a putative natural modulator of PPARγ: exploring a nutrient-based approach for type 2 diabetes. (PubMed, Front Pharmacol) - "Functionally, in 3T3-L1 adipocytes, thiamine induced adipogenesis and PPARγ-response element binding with a potency analogous to rosiglitazone, suggesting direct agonistic activity. Corroborating these mechanistic insights at the clinical level, a new meta-analysis of randomized controlled trials demonstrates that high-dose benfotiamine, a synthetic thiamine derivative, significantly improves neuropathic and vascular outcomes in T2D patients. While the contribution of thiamine's established antioxidant effects to these clinical benefits cannot be ruled out, the synergy of computational, cellular, and human evidence provides a compelling foundation for our hypothesis. This study suggests that thiamine could act as a PPARγ ligand and serve as a safer treatment option for metabolic disorders, which needs to be tested in vivo."

Journal • Diabetes • Inflammation • Metabolic Disorders • Type 2 Diabetes Mellitus • PPARG

A Retrospective Study of the Association between Low Vitamin B1 in the Blood and Cognitive Impairment in Patients with Alzheimer's Disease. (PubMed, J Nutr Sci Vitaminol (Tokyo)) - "While benfotiamine, a lipid-soluble VB1 derivative, has been suggested to improve cognition, its causal effect remains uncertain due to the study's cross-sectional design. Selection bias and the lack of dietary data are also limitations. Further longitudinal research is needed to determine whether VB1 supplementation could help mitigate cognitive decline in AD patients."

Journal • Observational data • Retrospective data • Alzheimer's Disease • CNS Disorders • Cognitive Disorders

Potential of Benfotiamine in the treatment of neuropsychological disorders. (PubMed, Mol Biol Rep) - "In this narrative review, we provide a comprehensive overview of the cellular and molecular pathways modulated by benfotiamine in the context of neuropsychiatric disorders. Specifically, we highlight its effects on oxidative stress, inflammatory signaling, mitochondrial function, glucose metabolism, and advanced glycation end-product (AGE) formation, all of which contribute to its neuroprotective and potentially therapeutic properties."

Journal • Review • Alzheimer's Disease • CNS Disorders • Inflammation • Mental Retardation • Psychiatry

Evaluation of the protective effect of Benfotiamine against neurotoxic effects, depression and oxidative stress induced by noise exposure. (PubMed, Sci Rep) - "Benfotiamine also appears to be more effective than N-acetylcysteine in reducing noise exposure effects. The findings confirm that noise contributes to oxidative stress in the brain and the development of depressive-like behaviors, while also highlighting the protective effects of Benfotiamine against noise-induced damage."

Journal • CNS Disorders • Depression • Mood Disorders • Psychiatry

Thiamine Compounds Alleviate Oxidative Stress, Over-Expression of Pro-Inflammatory Markers and Behavioral Abnormalities in a Mouse Predation Model of PTSD. (PubMed, Int J Mol Sci) - "Treatment with thiamine or benfotiamine significantly ameliorated most of these changes in the stressed groups. Thus, thiamine compounds may have therapeutic potential in patients with PTSD, owing to their antioxidant and anti-inflammatory properties."

Biomarker • Journal • Preclinical • CNS Disorders • Inflammation • Mood Disorders • Pain • Post-traumatic Stress Disorder • Psychiatry • FOS • IL1B

Transketolase Activation Improves Fatty Liver Ischemia Reperfusion Injury by Inhibiting Ferroptosis via Ncoa4 Downregulation (WTC 2025) - "Further, TKT activation with benfotiamine could protect from hepatocytes injury in vivo and in vitro... TKT plays an important role in fatty liver IRI. TKT activation could primarily alleviating ferroptosis in fatty liver transplantation via inhibition of Ncoa4 expression."

Cardiovascular • Hepatology • Liver Failure • Reperfusion Injury • NCOA4

Protective effects of benfotiamine supplementation and aerobic training against noise-induced cardiovascular damage: A focus on oxidative stress and inflammatory pathways. (PubMed, Biochem Biophys Res Commun) - "Our findings suggest that BFT's antioxidant and anti-inflammatory properties, in combination with MICT as a non-pharmacological approach, may protect against noise-induced cardiovascular problems. BFT and MICT mitigate noise-induced cardiac injury via antioxidant and anti-inflammatory mechanisms, with additive benefits evident in the combined treatment group."

Journal • Cardiovascular • IL1B • IL6 • TNFA

Early diagnosis and effective therapy of diabetic polyneuropathy (PubMed, Zh Nevrol Psikhiatr Im S S Korsakova) - "The pathogenetic therapy of DPN includes the use of alpha-lipoic acid and benfotiamine, the effectiveness of which has been shown in clinical studies. Adjuvant analgesics are used as symptomatic therapy, namely drugs from the group of antiepileptic drugs (gabapentin, pregabalin) and antidepressants (duloxetine). Doctors' knowledge of the problem of diagnosis and treatment of DPN will make it possible to detect this disease at an early stage and effectively control the progression of symptoms."

Journal • Review • Diabetes • Diabetic Neuropathy • Gene Therapies • Metabolic Disorders • Pain

Benfotiamine prevents endotoxin-induced cytotoxicity in human dermal fibroblasts (SID 2025) - "Future experiments will explore benfotiamine's effects on apoptotic signaling by examining caspase-3 activation, PARP cleavage, and the expression of apoptotic markers. Additional in-vivo studies are planned to determine the therapeutic potential of benfotiamine in improving wound healing."

Diabetes • Infectious Disease • Metabolic Disorders • CASP3

Benfotiamine, a Lipid-Soluble Derivative of Vitamin B1, Ameliorates the Carbohydrate Overload-Induced Mitochondrial Dysfunction in Fish Megalobrama amblycephala by Triggering the ULK1-Mediated Mitophagy. (PubMed, Aquac Nutr) - "However, benfotiamine treatment increased the contents of P-AMPK, P-ULK1, and the PINK1-Parkin pathway-related proteins as well as mitochondrial complex activities. In conclusion, benfotiamine could trigger the ULK1-mediated mitophagy to ameliorate the carbohydrate overload-induced mitochondrial dysfunction in fish."

Journal • Diabetes • Metabolic Disorders • PTEN • ULK1

UH Cleveland Medical Center Currently Recruiting People with Early Alzheimer’s Disease for a Clinical Trial Evaluating Benfotiamine, a Synthetic Version of Thiamine (Vitamin B1) - "University Hospitals (UH) Cleveland Medical Center is conducting a new, national Alzheimer’s disease (AD) clinical research study evaluating the potential benefits of benfotiamine, a synthetic version of thiamine or vitamin B1, as a treatment for mild cognitive impairment (MCI) or early AD. The Phase 2 study, called BenfoTeam, will evaluate the effects of benfotiamine on cognitive function and preservation and/or potential improvement in daily routine activities....The trial also provided preliminary evidence of the efficacy of benfotiamine on cognitive and functional outcomes that were encouraging data to support the need for this Phase 2 study."

Trial status • Alzheimer's Disease

Evaluation of neuroprotective role of benfotiamine in Alzheimer's disease model: A randomized control study. (PubMed, Clin Ter) - "Positive control group received donepezil; BFT groups received 50 and 300 mg/kg b.w. /day for last 15 days. It can be concluded that oral supplementation of 300mg /kg b.w. /day of BFT may reverse AD pathological processes and improve dementia. However, the need of thiamine supplementation in elderly persons to delay or halt the cognitive loss and eventual dementia needs validation by clinical trial."

Clinical • Journal • Alzheimer's Disease • CNS Disorders • Cognitive Disorders • Dementia • Pain • CASP8

Unravelling advanced glycation end products as emerging therapeutic targets in diabetic retinopathy management. (PubMed, Eur J Ophthalmol) - "Existing drugs such as pioglitazone, angiotensin II receptor blockers, ACE inhibitors, calcium channel blockers, and statins, along with natural compounds like benfotiamine and cinnamon bark extract, show promise as anti-AGE strategies. This multifaceted approach presents a paradigm shift in early diabetic retinopathy treatment, with ongoing research focusing on refining these strategies for improved management."

Journal • Diabetes • Diabetic Retinopathy • Inflammation • Metabolic Disorders • Ophthalmology • Pediatrics • Retinal Disorders

Benfotiamine Ameliorates Streptozotocin-Induced Alzheimer's Disease in Rats by Modulating Neuroinflammation, Oxidative Stress, and Microglia. (PubMed, Mol Neurobiol) - "Supplementation with 150 mg/kg of BFT for 7 days significantly reduced inflammation in the hippocampus and provided protection against oxidative damage in the entorhinal cortex by activating the Nrf-2 pathway and enhancing the expression of antioxidant enzymes such as SOD1 and CAT. These findings suggest that BFT exerts neuroprotective effects in AD, particularly impacting glial cell function and redox homeostasis."

Journal • Preclinical • Alzheimer's Disease • CNS Disorders • Dementia • Inflammation

Drug Development. (PubMed, Alzheimers Dement) - "Benfotiamine reverses the changes of metabolites/lipids reflecting AD progression. Our ongoing NIH funded multicenter trial includes blood biomarkers of thiamine, amyloid, tau, inflammation, neurodegeneration, AGE, and extensive cognitive testing. A larger sample size is necessary to test whether metabolic biomarkers are useful for disease diagnosis, prognosis, and monitoring therapeutic efficacy. This research was partially funded by National Institute of Aging R01AG043679 (G.E.G), AG014930 (G.E.G, S.Z) and R01 AG076634 (GEG, HF, JAL)."

Journal • CNS Disorders • Cognitive Disorders • Inflammation

Drug Development. (PubMed, Alzheimers Dement) - "BenfoTeam deploys an innovative seamless phase 2A-2B design to achieve its overall aim of clinical POC. With its early adaptive dose decision, exposure will be optimized to the highest tolerated dose. A positive phase 2 POC trial that is powered to achieve a clinically significant benefit will further validate our approach."

Journal • Alzheimer's Disease • CNS Disorders • Dementia

A Trial to Evaluate the Safety and Efficacy of Benfotiamine in Patients With Early Alzheimer's Disease (BenfoTeam) (clinicaltrials.gov) - P2 | N=406 | Recruiting | Sponsor: Alzheimer's Disease Cooperative Study (ADCS) | Trial completion date: Feb 2027 ➔ Dec 2027 | Trial primary completion date: Feb 2027 ➔ Dec 2027

Trial completion date • Trial primary completion date • Alzheimer's Disease • CNS Disorders

Benfotiamine Supplementation Increases Thiamine in Muscle of Endurance-Trained Mice and Affects the Energy Metabolism. (PubMed, J Nutr Metab) - "Benfotiamine supplementation increases thiamine levels in erythrocytes and muscle but does not affect the gene expression of thiamine-dependent enzymes. Although it alters energy metabolism in trained muscle, it does not enhance endurance performance in mice."

Journal • Preclinical

Pharmacological Doses of Thiamine Benefit Patients with the Charcot-Marie-Tooth Neuropathy by Changing Thiamine Diphosphate Levels and Affecting Regulation of Thiamine-Dependent Enzymes. (PubMed, Biochemistry (Mosc)) - "Single cases of administration of sulbutiamine (200 mg) or benfotiamine (150 mg) reveal their effects on the assayed parameters within those of thiamine...Correlation analysis revealed sex-specific differences in the relationship between the parameters of thiamine status in both the control subjects and patients with the CMT disease. Thus, our findings link physiological benefits of thiamine administration in CMT patients to changes in their thiamine status, in particular, the blood levels of ThDP and transketolase regulation."

Journal • Genetic Disorders • Pain

Benfotiamine Inhibits Neuro-immune Activation to Alleviate Paclitaxel-Induced Neuropathic Pain (IASP 2024) - "These findings provide an evidence for antinociceptive potential of benfotiamine partly by inhibiting neuro-immune activation and in part by reducing oxido-nitrosative stress in paclitaxel-induced neuropathy and represent a novel therapeutic approach for alleviation of CINP clinically."

Immunology • Neuralgia • Pain • Peripheral Neuropathic Pain

The protective effect of benfotiamine on gastric ulcers in male rats: an experimental study. (PubMed, J Mol Histol) - "In this study, 30 Wistar male rats were divided randomly into six groups: control (normal), indomethacin, omeprazole, and treatment groups, including 50, 100, and 200 mg/kg of benfotiamine. Moreover, benfotiamine at 100 and 200 mg/kg effectively attenuated the levels of pro-inflammatory cytokines IL-6 and TNF-α and oxidative stress markers MDA and ROS while increasing the antioxidant GSH. These findings suggest that benfotiamine's gastroprotective effects are mediated through its antioxidant and anti-inflammatory properties, which help mitigate the tissue damage and inflammatory response associated with indomethacin-induced gastric ulcers.However, further research is needed to elucidate the precise molecular mechanisms underlying these beneficial effects and to evaluate the potential therapeutic application of benfotiamine in clinical settings."

Journal • Preclinical • Gastric Cancer • Gastroenterology • Gastrointestinal Cancer • Gastrointestinal Disorder • Inflammation • Oncology • Peptic Ulcer • Solid Tumor • IL6 • TNFA

Benfotiamine protects MPTP-induced Parkinson's disease mouse model via activating Nrf2 signaling pathway. (PubMed, PLoS One) - "Control of Nrf2 proved crucial for BFT, as it facilitated Nrf2 movement to the nucleus, upregulating antioxidant genes and enzymes while mitigating oxidative damage. This study elucidates BFT's neuroprotective effects in a PD mouse model via Nrf2-mediated antioxidant mechanisms and gene expression modulation, underscoring its potential as a therapeutic agent for PD."

Journal • Preclinical • CNS Disorders • Movement Disorders • Parkinson's Disease • NLRP3 • NQO1

Exploring the Therapeutic Potential of Benfotiamine in a Sporadic Alzheimer's-Like Disease Rat Model: Insights into Insulin Signaling and Cognitive function. (PubMed, ACS Chem Neurosci) - "We attribute these effects to BFT's ability to modulate glucose transporters type 1 and 3 (GLUT1 and GLUT3) in the hippocampus, inhibit GSK3 activity in the hippocampus, and modulate the insulin signaling in the hippocampus and entorhinal cortex, as well as reduce the activation of apoptotic pathways (BAX) in the hippocampus. Therefore, BFT emerges as a promising and accessible intervention in the initial treatment of conditions similar to AD."

Journal • Preclinical • Alzheimer's Disease • CNS Disorders • Cognitive Disorders • Diabetes • Metabolic Disorders • SLC2A1 • SLC2A3

A Seamless Phase 2A-Phase 2B Multi-Center Trial to Test the Benefits of Benfotiamine on the Progression of Alzheimer's Disease-Benfoteam: Design and Methods (AAIC 2024) - "BenfoTeam deploys an innovative seamless phase 2A-2B design to achieve its overall aim of clinical POC. With its early adaptive dose decision, exposure will be optimized to the highest tolerated dose. A positive phase 2 POC trial that is powered to achieve a clinically significant benefit will further validate our approach."

Clinical • P2a data • P2b data • Alzheimer's Disease • CNS Disorders • Dementia

PHARMACOLOGICAL THIAMINE (Vitamin B1) AS A TREATMENT FOR ALZHEIMER’S DISEASE (AAIC 2024) - "Benfotiamine reverses the changes of metabolites/lipids reflecting AD progression. Our ongoing NIH funded multicenter trial includes blood biomarkers of thiamine, amyloid, tau, inflammation, neurodegeneration, AGE, and extensive cognitive testing. A larger sample size is necessary to test whether metabolic biomarkers are useful for disease diagnosis, prognosis, and monitoring therapeutic efficacy."

Alzheimer's Disease • CNS Disorders • Cognitive Disorders • Inflammation